ESMO Asia 2023 | Predicting MK-2206 response in patients with breast cancer

Jiang Zhang, PhD, The Hong Kong Polytechnic University, Hong Kong, China examines the results of the secondary radio-genomics analysis of the I-SPY2 trial (NCT01042379) that tested new drugs in patients with high-risk breast cancer. Contrast-enhanced magnetic resonance imaging (DCE-MRI) has produced highly significant predictive values for the existing breast cancer biomarkers HER2-, HR-, HER2-/HR-, and MammaPrint (MP)2 with Akt inhibitor MK-2206 response, which has resulted in significant increases in pathological complete response in comparison to those in the original trial. This study is highly relevant in aiding our understanding of the comprehensive values of these biomarkers. This interview took place at the European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.